Therapy Optimization in Multiple Sclerosis (MS)
Completed
- Conditions
- Multiple Sclerosis
- Interventions
- Registration Number
- NCT00819000
- Lead Sponsor
- Teva Neuroscience, Inc.
- Brief Summary
The purpose of this study is to determine if higher compliance and adherence rates to drug therapy for MS result in better health outcomes than lower rates of therapy compliance and adherence.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2878
Inclusion Criteria
- Male or female, 18 years of age or older, with a diagnosis of MS.
- Being treated with Glatiramer Acetate (GA) or (IFN)-β
- Receiving therapy from a participating Specialty Pharmacy
Exclusion Criteria
- Has any contraindication to GA or IFN-β therapy, including pregnancy, trying to become pregnant, or breast feeding during the study
- Has received an experimental drug in the last thirty (30) days other than Fampridine SR (4-aminopyridine or 4-AP)
- Unlikely to be able to participate for the full two years of the study
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Treated MS Subjects Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b Subjects who are treated with Glatiramer Acetate or Interferon (IFN)-β and receive their therapy from one of the participating Specialty Pharmacies
- Primary Outcome Measures
Name Time Method Relationship of therapy Medication Possession Ratio (MPR), to patient outcomes 12 months and 24 months
- Secondary Outcome Measures
Name Time Method Relationship of therapy adherence, defined as the accumulation of time from initiation to discontinuation of therapy and measured by time, to patient outcomes 12 months and 24 months
Trial Locations
- Locations (1)
Teva Investigational Site
🇺🇸Carnegie, Pennsylvania, United States